Scott W Canna Selected Research

Macrophage Activation Syndrome

2/2022	Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation.
1/2022	Excess Serum Interleukin-18 Distinguishes Patients With Pathogenic Mutations in PSTPIP1.
1/2022	Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
12/2021	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction.
4/2021	Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction.
7/2020	Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019.
2/2020	IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.
1/2020	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases.
1/2020	IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome.
1/2020	Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott W Canna Research Topics

Disease

15	Macrophage Activation Syndrome 02/2022 - 07/2013
7	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2022 - 05/2014
6	Inflammation (Inflammations) 01/2018 - 08/2006
3	Communicable Diseases (Infectious Diseases) 01/2022 - 11/2020
3	Enterocolitis 01/2022 - 12/2017
3	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2017 - 01/2012
2	Sepsis (Septicemia) 02/2022 - 01/2022
2	Familial Mediterranean Fever (Periodic Disease) 01/2022 - 01/2018
2	Lung Diseases (Lung Disease) 01/2022 - 07/2020
2	Vascular System Injuries 12/2021 - 04/2021
2	Thrombotic Microangiopathies 12/2021 - 04/2021
2	Macular Degeneration (Age-Related Maculopathy) 12/2021 - 01/2017
2	Cytopenia 01/2021 - 01/2020
2	Infections 01/2021 - 01/2018
2	Hepatitis 07/2020 - 11/2019
2	Cytokine Release Syndrome 01/2020 - 03/2016
2	Fever (Fevers) 01/2020 - 10/2014
2	Adult-Onset Still's Disease 01/2018 - 05/2014
2	Anemia 03/2016 - 07/2013
2	Cryopyrin-Associated Periodic Syndromes 10/2014 - 08/2006
1	Disseminated Intravascular Coagulation 02/2022
1	Septic Shock (Toxic Shock Syndrome) 02/2022
1	Eosinophilia 01/2022
1	Pyogenic arthritis, pyoderma gangrenosum, and acne 01/2022
1	Noncommunicable Diseases 12/2021
1	Retinal Degeneration 12/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2021
1	COVID-19 11/2021
1	Neutropenia 01/2021
1	Bone Marrow Failure Disorders 01/2021
1	Virus Diseases (Viral Diseases) 11/2020
1	Dermatomyositis (Dermatopolymyositis) 01/2020
1	Pulmonary Alveolar Proteinosis 01/2020
1	Dysbiosis 11/2019
1	Disease Progression 11/2019
1	Ulcer 01/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Choroidal Neovascularization 01/2017
1	Weight Loss (Weight Reduction) 03/2016
1	Thrombocytopenia (Thrombopenia) 03/2016
1	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2015
1	Myositis (Idiopathic Inflammatory Myopathies) 07/2015
1	Arthritis (Polyarthritis) 01/2013
1	Exanthema (Rash) 08/2006
1	Body Weight (Weight, Body) 08/2006

Drug/Important Bio-Agent (IBA)

11	Interleukin-18 (Interleukin 18)IBA 01/2022 - 07/2015
6	Biomarkers (Surrogate Marker)IBA 02/2022 - 01/2020
6	InflammasomesIBA 01/2022 - 10/2014
5	CytokinesIBA 01/2022 - 01/2012
4	InterferonsIBA 01/2022 - 07/2013
4	Proteins (Proteins, Gene)FDA Link 12/2021 - 08/2006
3	ProteomeIBA 01/2022 - 04/2021
3	Interleukin-1 (Interleukin 1)IBA 07/2020 - 07/2015
2	PyrinIBA 01/2022 - 01/2018
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021 - 08/2006
2	AutoantibodiesIBA 01/2020 - 07/2015
2	Toll-Like Receptors (Toll-Like Receptor)IBA 07/2013 - 01/2012
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 02/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	ElementsIBA 12/2021
1	Ferritins (Ferritin)IBA 01/2021
1	Toll-Like Receptor 8IBA 01/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021
1	Chimeric Antigen ReceptorsIBA 11/2020
1	Interleukin-6 (Interleukin 6)IBA 07/2020
1	Biological ProductsIBA 07/2020
1	Adenosine DeaminaseIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 11/2019
1	LigandsIBA 11/2019
1	Granzymes (Granzyme)IBA 01/2018
1	veltuzumabIBA 01/2018
1	PerforinIBA 01/2018
1	Toll-Like Receptor 9IBA 01/2017
1	Interleukin-10 (Interleukin 10)IBA 01/2017
1	InterleukinsIBA 03/2016
1	Janus KinasesIBA 03/2016
1	ruxolitinibIBA 03/2016
1	Interferon Type IIBA 07/2015
1	NucleotidesIBA 10/2014
1	A 17 (A-17)IBA 01/2013
1	Interleukin-1beta (Interleukin 1 beta)IBA 08/2006

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2020
3	Critical Care (Surgical Intensive Care) 01/2022 - 11/2020
1	Cell Transplantation 01/2021
1	Injections 08/2006